B7-1/CD80 Antibody (IDEC-114 (Galiximab)) - Chimeric - Azide and BSA Free

Immunocytochemistry/Immunofluorescence: B7-1/CD80 Antibody (IDEC-114 (Galiximab)) - Chimeric [NBP2-81100] - Immunofluorescence staining of fixed Daudi cells with B7-1/CD80 Antibody (IDEC-114 (Galiximab)) [NBP2-81100]. Immunofluorescence analysis of paraformaldehyde fixed Daudi cells on Shi-fix coverslips, permeabilized with 0.15% Triton and stained with the chimeric rabbit IgG version of IDEC-114 (Galiximab) [NBP2-81100] at 10 ug/ml for 1h followed by Alexa Fluor 488 secondary antibody (1 ug/ml), showing membrane staining. The nuclear stain is DAPI (blue). Panels show from left-right, top-bottom NBP2-81100, DAPI, merged channels and an isotype control. The isotype control was stained with an anti-Fluorescein antibody followed by Alexa Fluor 488 secondary antibody.

• Reactivity: Hu
• Applications: WB, ELISA, Flow, Func, ICC/IF, IHC, IP, B/N
• Clone: IDEC-114 (Galiximab)
• Clonality: Monoclonal
• Host: Rabbit
• Conjugate: Unconjugated
• Format: Azide and BSA Free
• Concentration: 1 mg/ml

B7-1/CD80 Antibody (IDEC-114 (Galiximab)) - Chimeric - Azide and BSA Free Summary

• Description: Novus Biologicals Rabbit B7-1/CD80 Antibody (IDEC-114 (Galiximab)) - Chimeric - Azide and BSA Free (NBP2-81100) is a recombinant monoclonal antibody validated for use in IHC, WB, ELISA, Flow, ICC/IF and IP. All Novus Biologicals antibodies are covered by our 100% guarantee.
• Additional Information: Recombinant Monoclonal Antibody
• Immunogen: Galiximab was prepared by immunizing cynomolgus monkeys with recombinant B7-1/CD80 antigen. The variable regions of the light and heavy chains were then cloned by being incorporated into a cassette vector (N5LG1) containing human constant region genes and subsequently transfected into the Dg44 CHO cell line (Hariharan K, 2013)
• Specificity: Galiximab is a primatized mAb which consists of human constant and primate (cynomolgus macaque) variable regions and binds specifically to B7-1/CD80. B7-1/CD80 is a surface glycoprotein and a member of the B7 family of costimulatory molecules. B7-1/CD80 antigen regulates T cell activation (through interacting with CD28 or CD152) and is expressed transiently in antigen-presenting cells, T cells and normal B cells, and expressed consitutively on various subtypes of B-cell lymphomas.
• Isotype: IgG Lambda
• Clonality: Monoclonal
• Host: Rabbit
• Gene: CD80
• Purity: Protein A purified

Applications/Dilutions

• Dilutions:
  • Block/Neutralize
  • ELISA
  • Flow Cytometry
  • Functional
  • Immunocytochemistry/ Immunofluorescence
  • Immunohistochemistry
  • Immunoprecipitation
  • Western Blot
• Application Notes: This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. Galiximab acts to decrease in cell proliferation, inhibition of the constitutively active NF-kappaB pathway, increase in apoptosis and ADCC against various B-cell lymphoma cell lines. Galiximb affects CD28 and CD152 interactions with CD80. This antibody can also be used for FC, WB, ELISA, IP and IHC.

Packaging, Storage & Formulations

• Storage: Store at 4C for up to 3 months. For longer storage, aliquot and store at -20C.
• Buffer: PBS
• Preservative: 0.02% Proclin 300
• Concentration: 1 mg/ml
• Purity: Protein A purified

Alternate Names for B7-1/CD80 Antibody (IDEC-114 (Galiximab)) - Chimeric - Azide and BSA Free

• Activation B7-1 antigen
• B7
• B71
• B7-1
• BB1
• CD28LG1
• CD28LGB7-1 antigen)
• CD80 antigen
• CD80 molecule
• CD80
• costimulatory factor CD80
• costimulatory molecule variant IgV-CD80
• CTLA-4 counter-receptor B7.1
• T-lymphocyte activation antigen CD80

Background

The B-lymphocyte activation antigen B7-1 (CD80) provides regulatory signals for T lymphocytes as a consequence of binding to the CD28 and CTLA4 ligands of T cells. After engagement of T-cell receptor with antigen in association with major histocompatibility complex class II, a second signal mediated through the binding of B7 to CD28 greatly upregulates the production of multiple lymphokines (1). The relatively small CTLA-4/B7-1 binding interface exhibits an unusually high degree of shape complementarity. CTLA-4 forms homodimers through a newly defined interface of highly conserved residues. This zipper-like oligomerization provides the structural basis for forming unusually stable signalling complexes at the T-cell surface, underscoring the importance of potent inhibitory signalling in human immune responses (2).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: CD80